Automated Closed System for Genetically Modified T Cell Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical manufacturing of gene-modified T cells is complex, labor-intensive, and requires skilled operators, limiting its scalability and availability due to the need for dedicated infrastructure and high skill demands, restricting its broad development and application.
Innovation Solution
An automated process using a closed GMP-compliant system, such as the CliniMACS Prodigy, for cell processing, which includes steps like cell preparation, separation, activation, expansion, transduction, and formulation, reducing manual interventions and enhancing transduction efficiency and cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If manual processing methods are used for T cell manufacturing, then flexibility in process adjustment is maintained, but labor intensity increases and requires skilled operators
Solution Approach 1:
The system enables automated self-service processing where the closed system automatically performs cell separation, activation, transduction, and expansion without requiring manual intervention at each step, thereby reducing labor intensity while maintaining process control
Solution Approach 2:
Manual mechanical operations are replaced with automated robotic systems and computer-controlled interfaces that manage the entire T cell manufacturing process, eliminating the need for skilled operators to perform repetitive manual tasks
2Reliability
If dedicated infrastructure with clean rooms is used, then sterile containment is ensured, but device complexity and infrastructure requirements increase
Solution Approach 1:
The system creates a closed, sterile environment that maintains inert and controlled conditions throughout the manufacturing process, eliminating the need for extensive clean room infrastructure while ensuring sterile containment through sealed chambers and controlled access ports
Solution Approach 2:
The closed system uses sealed chambers and flexible membranes to create sterile barriers that contain cells and reagents, providing reliable sterile containment without requiring rigid clean room structures
3Manufacturing precision
If multiple manual handling steps are performed, then process flexibility is maintained, but transduction efficiency decreases due to cell stress
Solution Approach 1:
Multiple separate handling steps are merged into a continuous automated process within the closed system, where cell separation, activation, and transduction occur in sequence without removal from the sterile environment, reducing cell stress and improving transduction efficiency
Solution Approach 2:
The system maintains continuous processing where cells remain in the closed system throughout the manufacturing process, eliminating interruptions and repeated handling that would otherwise stress the cells and reduce transduction efficiency
4Productivity
If automated processing is implemented, then labor requirements are reduced, but manufacturing complexity increases
Solution Approach 1:
The automated system integrates multiple functions including cell separation, activation, transduction, and expansion within a single closed platform, reducing the need for multiple separate devices and simplifying the overall automation architecture while maintaining high productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The automated process achieves higher transduction efficiency and robust manufacturing of genetically modified T cells, reducing the need for skilled operators and infrastructure, enabling the generation of clinically relevant cell numbers in a shorter time with improved cell viability and purity.
Implementation Method 1
magnetic separation of the T cells, T cell subsets and/or T cell progenitors
Implementation Method 2
preparation of the cell sample by centrifugation
Data Source
AI summary
The present invention provides a process for generation of genetically modified T cells, T cell subsets and/or T cell progenitors comprising the steps: a) providing a cell sample comprising T cells, T cell subsets and/or T cell progenitors b) preparation of the cell sample by centrifugation c) magnetic separation of the T cells, T cell subsets and/or T cell progenitors d) activation of the enriched T cells, T cell subsets and/or T cell progenitors using modulatory agents e) genetic modification of the T cells, T cell subsets and/or T cell progenitors f) expansion of the genetically modified T cells, T cell subsets and/or T cell progenitors in a cultivation chamber g) washing of the cultured T cells, T cell subsets and/or T cell progenitors characterized in that all steps are performed in a closed and sterile cell culture system.